Pre-Diabetes among HIV-Infected Individuals Receiving HAART: Prevalence, Diagnostic Tests, and Associated Factors, a Cross-Sectional Study
Background: In our common practice we use highly active antiretroviral therapy (HAART) which has resulted in a dramatic decrease in mortality and morbidity in HIV-infected patients. Components of HAART, as well as HIV infection itself, can have significant effects on developing new-onset diabetes and this risk will increase if the patient has a positive family history of diabetics. Objective: To determine the frequency of prediabetes among HIV-infected individuals. Methods: A cross-sectional study was conducted through a Non-probability consecutive sampling technique. A retrospective descriptive study was performed on 374 cases in the tertiary care centre in Lahore, Pakistan from September 2020 to April 2021 Results: The association between the prevalence of prediabetes and risk factors was analyzed. Among 374 HIV-infected patients, the mean age was 37.80 years, and 65% were male and 45% were female. Pre-diabetic patients’ means were 1.34 ± 0.477.family history of diabetics 1.34 ± 0.728. Linear correlation was seen between duration of HIV treatment and pre-diabetics, duration of HIV treatment, and marital status of the patient. Family history of diabetic Mellitus is correlated with age, pre-Diabetics with marital status. Conclusion: A high prevalence of prediabetes was observed in this cohort of HIV-infected patients. HAART regimes should be avoided in HIV-infected patients at high risk of developing diabetes, e.g., especially those with a history of positive family history of diabetes, or impaired OGTT. The regime should be avoided, and replaced with less toxic drugs.